Treatment satisfaction of diabetic patients: what are the contributing factors?

Biderman, Aya; Noff, Enav; Harris, Stewart B.; Friedman, Nir; Levy, Amalia

doi:10.1093/fampra/cmp007

Cited by 122 publications

(155 citation statements)

References 14 publications

Supporting

Mentioning

128

Contrasting

Unclassified

Order By: Relevance

“…Satisfaction and efficacy of switching from daily dipeptidyl peptidase-4 inhibitors to weekly trelagliptin in patients with type 2 diabetes -Randomized controlled studyMayuko Oita 1) , Hideaki Miyoshi 1) , Kota Ono 2) , Akinobu Nakamura 1) , Kyu Yong Cho 1), 2) , Hiroshi Nomoto 1) , Kohei Yamamoto 1) , Kazuno Omori 1) , Naoki Manda 3) , Yoshio Kurihara 4) , Shin Aoki 5) and Tatsuya Atsumi 1) intensive metabolic controls, especially adequate glycemic control, are necessary [1]. Therefore, it is important for patients to maintain a favorable lifestyle and continue the necessary treatment with good medication adherence over a long period time.…”

mentioning

confidence: 99%

“…Therefore, it is important for patients to maintain a favorable lifestyle and continue the necessary treatment with good medication adherence over a long period time. Patients who are dissatisfied with their treatment are less likely to adhere to that treatment [2,3], and non-adherence to treatments for type 2 diabetes can result in poor glycemic control [4][5][6][7], which increases the risk of complications leading to disease deterioration.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Satisfaction and efficacy of switching from daily dipeptidyl peptidase-4 inhibitors to weekly trelagliptin in patients with type 2 diabetes—Randomized controlled study—

et al. 2018

View full text Add to dashboard Cite

Abstract. We compared treatment satisfaction between daily dipeptidyl peptidase-4 (DPP-4) inhibitors and a weekly DPP-4 inhibitor in patients with type 2 diabetes. The study was a 12-week, open-label, randomized, multicenter, controlled trial. Participants were Japanese patients with type 2 diabetes who had received daily DPP-4 inhibitors for more than 3 months. Patients were randomly assigned to a treatment cohort: (1) a group that continued taking daily DPP-4 inhibitors (daily group); or (2) a group that switched from daily DPP-4 inhibitors to a weekly DPP-4 inhibitor, trelagliptin (weekly group). The primary outcome was the change in treatment satisfaction levels from baseline to 12 weeks between the two groups, according to Diabetes Treatment Satisfaction Questionnaire (DTSQ) and Diabetes Therapy-Related Quality of Life (DTR-QOL) questionnaire scores. The changes in glycemic control and body weight were also assessed. Of 49 patients initially enrolled in the study, 47 completed the study. The change in DTSQ scores in the weekly group was not significantly different from that in the daily group. However, the improvements in total score and subscale domains 1 and 2 in the DTR-QOL analysis, which relate to burden on social/daily activities and anxiety/dissatisfaction with treatment, were significantly greater in the weekly group than the daily group (p = 0.048, 0.013 and 0.045, respectively). Mean changes in glycated hemoglobin levels and body weight were comparable between the groups. Switching from daily DPP-4 inhibitors to a weekly DPP-4 inhibitor, trelagliptin, could partially improve treatment satisfaction levels in patients with type 2 diabetes without affecting glycemic control.

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

Satisfaction and efficacy of switching from daily dipeptidyl peptidase-4 inhibitors to weekly trelagliptin in patients with type 2 diabetes—Randomized controlled study—

et al. 2018

View full text Add to dashboard Cite

show abstract

“…51 A survey conducted among 630 diabetes patients also found that treatment satisfaction was lower in those taking insulin. 52 According to this survey, other factors independently associated with lower treatment satisfaction were female gender, diabetes complications and poor adherence. 52 The findings of this study cannot be generalized because of several limitations, including the observational, open-label design, the small sample size and the absence of a specific clinical evaluation of frailty.…”

Section: Discussionmentioning

confidence: 80%

“…52 According to this survey, other factors independently associated with lower treatment satisfaction were female gender, diabetes complications and poor adherence. 52 The findings of this study cannot be generalized because of several limitations, including the observational, open-label design, the small sample size and the absence of a specific clinical evaluation of frailty. However, the present study describes a group of difficult-to-treat, real-world patients who closely resemble those typically encountered in daily clinical practice.…”

Section: Discussionmentioning

confidence: 80%

Linagliptin is associated to increased treatment adherence and satisfaction in elderly outpatients with diabetes and advanced chronic kidney disease

et al. 2016

View full text Add to dashboard Cite

The treatment of diabetes in frail elderly patients with decreased renal function is challenging and insufficiently supported by evidence. Due to their good tolerability and low hypoglycemic risk, oral dipeptidyl peptidase-4 (DPP-4) inhibitors have emerged as a reasonable option for glycemic control in the elderly. The aim was to evaluate the efficacy and safety of linagliptin, a long acting, oral DPP-4 inhibitor with a predominantly nonrenal elimination route, in elderly patients with severe chronic kidney disease (CKD). This was a retrospective, observational study in outpatients with type 2 diabetes and advanced-stage CKD (estimated glomerular filtration rate <30 mL/min per 1.73 m 2 ) referring to a diabetes clinic in Italy. Patients were switched from basal insulin to oral linagliptin 5 mg once daily and observed for 14 months. Assessed variables included glycemic control (HbA1c target, 7.5%-8.0%), adherence to treatment (Morisky questionnaire) and patient satisfaction (diabetes treatment satisfaction questionnaire). Adverse events, including hypoglycemic episodes, were also recorded. Thirty patients [mean (±standard deviation) age 70.2 (±8.2) years, HbA1c 7.6% (±0.3), fasting blood glucose 173.9 (±23.5) mg/dL] with type-2 diabetes and advanced CKD were included. The switch to linagliptin did not affect significantly glycemic control, was well tolerated and associated with a reduction in hypoglycemic episodes. Adherence to treatment was better with linagliptin than basal insulin and patient satisfaction significantly improved after switching. Linagliptin appears as a valid option for glycemic control in elderly diabetes patients with severe CKD in treatment with low-dose insulin. However adequately designed longterm studies are needed to confirm these findings.

show abstract

“…MedPodml 2018, 69(1): [15][16][17][18][19][20][21][22] telesnom masom, ukazujući da zadovoljstvo terapijom i te kako utiče na sam ishod lečenja (9,10). Zbog svoje prirode, toka, neophodnih životnih promena, dijabetes umnogome utiče na kvalitet života.…”

Section: Uvodunclassified

Analysis of treatment satisfaction among patients with type 2 diabetes

Babić¹,

Lukić²

2018

Medicinski podmladak

View full text Add to dashboard Cite

Introduction: Treatment of diabetes is complex and includes lifestyle intervention and pharmacologicalmanagement. Treatment satisfaction is a significant factor in improving health care. Special importance is given to diabetes because of its need for lifelong therapy.Aim: To determine the influence of certain socio-demographic and clinical factors on treatment satisfaction of patients with type 2 diabetes.Material and methods: A cross sectional study was conducted among 40 consecutive outpatients. Data was collected through two questionnaires. The first questionnaire consisted of socio-demographic and clinical data. The second one was a standardized Diabetes Treatment Satisfaction Questionnaire (DTSQs).Results: Of the studied patients, the majority were women (52,5%), patients in their sixties (55%), patients who only finished high school (55%), patients who were using insulinand OAD (50%), as well as patients who have developed chronic diabetic complications (80%). It was observed that treatment satisfaction among patients who have had diabetes for longer than twenty years was significantly lower than among those who have been treated for diabetes for less than ten years (4,30 ± 0,77 vs. 4,99 ± 0,63, p = 0,046). Patients who were taking tablets were significantly more satisfied with treatment (5,35 ± 0,38, p ˂ 0,001). Patients withoutany diabetic complication were significantly more satisfied with the treatment than those who have developed at least one diabetic complication (5,19 ± 0,87 vs. 4,59 ± 0,57, p = 0,023). Multiple regression analysis revealed that elementary education(p = 0,037), insulin (p ˂ 0,001) and any diabetic complication (p = 0,007) were independently associated with lower treatment satisfaction.Conclusion: Using DTSQ we noticed important socio-demographic and clinical factors that influence the satisfaction with the current therapy. Low educational level, insulin, having any diabetic complication and diabetes duration were associated with lower treatment satisfaction. Having identified this vulnerable group, we must place emphasis on the need of providing additional attention and assistance to these patients, in order to improve their health and clinical outcome.

show abstract

Treatment satisfaction of diabetic patients: what are the contributing factors?

Cited by 122 publications

References 14 publications

Satisfaction and efficacy of switching from daily dipeptidyl peptidase-4 inhibitors to weekly trelagliptin in patients with type 2 diabetes—Randomized controlled study—

Satisfaction and efficacy of switching from daily dipeptidyl peptidase-4 inhibitors to weekly trelagliptin in patients with type 2 diabetes—Randomized controlled study—

Linagliptin is associated to increased treatment adherence and satisfaction in elderly outpatients with diabetes and advanced chronic kidney disease

Analysis of treatment satisfaction among patients with type 2 diabetes

Contact Info

Product

Resources

About